Clinical Trial Update: Safety and Pharmacokinetics of Oral PRX-112 in Gaucher Disease Patients [Phase 1]

View source ↗

Summary

A Phase 1 study assessing the safety and pharmacokinetics of oral PRX-112 in Gaucher disease patients has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gaucher Disease

Drugs mentioned

• PRX-112

Snippet

Sponsor: Protalix | Conditions: Gaucher Disease | Phase 1 | Status: COMPLETED